A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Mar 26, 2026 - P3 | N=358 | Recruiting | Sponsor: Genrix (Shanghai) Biopharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting
Enrollment open • Hematological Malignancies • Multiple Myeloma • Oncology
|